204 related articles for article (PubMed ID: 25154405)
41. Epigenetic drugs take on cancer.
Kaiser J
Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
[No Abstract] [Full Text] [Related]
42. Epigenetic Therapeutics: A New Weapon in the War Against Cancer.
Ahuja N; Sharma AR; Baylin SB
Annu Rev Med; 2016; 67():73-89. PubMed ID: 26768237
[TBL] [Abstract][Full Text] [Related]
43. The combination of hypomethylating agents and histone deacetylase inhibitors (HDACi) are synergistically cytotoxic and reverse the malignant phenotype in preclinical models of T-cell lymphoma.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):9-11. PubMed ID: 24852790
[No Abstract] [Full Text] [Related]
44. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Rangwala S; Zhang C; Duvic M
Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
[TBL] [Abstract][Full Text] [Related]
45. Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
Thelen P; Krahn L; Bremmer F; Strauss A; Brehm R; Loertzer H
Int J Mol Med; 2013 Feb; 31(2):339-46. PubMed ID: 23292124
[TBL] [Abstract][Full Text] [Related]
46. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.
Mutze K; Langer R; Becker K; Ott K; Novotny A; Luber B; Hapfelmeier A; Göttlicher M; Höfler H; Keller G
Ann Surg Oncol; 2010 Dec; 17(12):3336-43. PubMed ID: 20585871
[TBL] [Abstract][Full Text] [Related]
47. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
48. A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
Leclercq S; Gueugnon F; Boutin B; Guillot F; Blanquart C; Rogel A; Padieu M; Pouliquen D; Fonteneau JF; Grégoire M
Eur Respir J; 2011 Nov; 38(5):1105-16. PubMed ID: 21540307
[TBL] [Abstract][Full Text] [Related]
49. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
[TBL] [Abstract][Full Text] [Related]
50. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Cowan LA; Talwar S; Yang AS
Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
[TBL] [Abstract][Full Text] [Related]
51. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
[TBL] [Abstract][Full Text] [Related]
52. Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements.
Singh D; Khan MA; Siddique HR
Epigenomics; 2023 Apr; 15(8):517-537. PubMed ID: 37313832
[TBL] [Abstract][Full Text] [Related]
53. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA
Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739
[TBL] [Abstract][Full Text] [Related]
54. Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.
Roulois D; Blanquart C; Panterne C; Gueugnon F; Grégoire M; Fonteneau JF
Eur J Immunol; 2012 Mar; 42(3):783-9. PubMed ID: 22144115
[TBL] [Abstract][Full Text] [Related]
55. Histone deacetylase inhibitors in lymphoma and solid malignancies.
Rasheed W; Bishton M; Johnstone RW; Prince HM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):413-32. PubMed ID: 18366289
[TBL] [Abstract][Full Text] [Related]
56. The failure of epigenetic combination therapy for cancer and what it might be telling us about DNA methylation inhibitors.
Yang AS; Yang BJ
Epigenomics; 2016 Jan; 8(1):9-12. PubMed ID: 26698294
[No Abstract] [Full Text] [Related]
57. Epigenetic therapy and chemosensitization in solid malignancy.
Ronnekleiv-Kelly SM; Sharma A; Ahuja N
Cancer Treat Rev; 2017 Apr; 55():200-208. PubMed ID: 28431263
[TBL] [Abstract][Full Text] [Related]
58. Clinical development of decitabine as a prototype for an epigenetic drug program.
Rosenfeld CS
Semin Oncol; 2005 Oct; 32(5):465-72. PubMed ID: 16210087
[TBL] [Abstract][Full Text] [Related]
59. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
Slingerland M; Guchelaar HJ; Gelderblom H
Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
[TBL] [Abstract][Full Text] [Related]
60. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.
Vendetti FP; Rudin CM
Expert Opin Biol Ther; 2013 Sep; 13(9):1273-85. PubMed ID: 23859704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
